Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Accelerate Diagnostics's Net Cash per Share or its related term are showing as below:
MEX:AXDX's Price-to-Net-Cash is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 9.3 * Ranked among companies with meaningful Price-to-Net-Cash only.
Accelerate Diagnostics (MEX:AXDX) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Accelerate Diagnostics Net Cash per Share Related Terms
Accelerate Diagnostics Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Accelerate Diagnostics's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:AXDX vs MSIU, BIOLQ, AFIB: Net Cash per Share Comparison
For the Medical Devices subindustry, Accelerate Diagnostics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accelerate Diagnostics Price-to-Net-Cash vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Accelerate Diagnostics's Price-to-Net-Cash falls into.
Accelerate Diagnostics Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Accelerate Diagnostics's Net Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accelerate Diagnostics (MEX:AXDX) has a Net Cash per Share of MXN-56.55 as of Dec. 2024. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Accelerate Diagnostics and its competitors.
Is Accelerate Diagnostics' Net Cash per Share too high?
Accelerate Diagnostics' current Net Cash per Share is MXN-56.55. Overall, Accelerate Diagnostics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Accelerate Diagnostics' Net Cash per Share compare to MSIU and BIOLQ?
Accelerate Diagnostics' Net Cash per Share of MXN-56.55 can be compared against companies in the Medical Devices & Instruments industry. The industry median Net Cash per Share is 9.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Devices & Instruments company?
The median Net Cash per Share among Medical Devices & Instruments companies is 9.30, based on 294 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Accelerate Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Net Cash per Share is 9.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accelerate Diagnostics's current Net Cash per Share is MXN-56.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accelerate Diagnostics stock overvalued right now?
Accelerate Diagnostics (MEX:AXDX) has a current Net Cash per Share of MXN-56.55. The current Net Cash per Share is MXN-56.55. Accelerate Diagnostics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Accelerate Diagnostics (MEX:AXDX), the current Net Cash per Share is MXN-56.55 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.
12GF Score
Get the complete analysis for MEX:AXDX
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:AXDX has been successfully added to your 
